

# Prognostic impact of *EGFR* and *KRAS* mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil

Impacto prognóstico das mutações de *EGFR* e *KRAS* na sobrevivência do câncer pulmonar na era pré-tki: o cenário real em um centro público de câncer de referência no Brasil

Thais Abreu Almeida<sup>1</sup>, Jeanine Marie Nardin<sup>1</sup>, Amanda Jurgensen<sup>2</sup>, Janaina Takahashi<sup>2</sup>, Juliana Jung<sup>1</sup>, Grazielle Losso<sup>3</sup>, José C. Casali-da-Rocha<sup>1</sup>.

## ABSTRACT

**Objective:** To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems important to provide regulatory agencies with epidemiological and prognostic information to guide future health policies and guidelines in Brazil. This work aims to characterize *EGFR* and *KRAS* mutations in NSCLC and associating them with patients demographic and tumor clinical-pathologic features. **Methods:** From 2004 to 2017, 237 metastatic NSCLC patients treated at Erasto Gaertner Cancer Hospital were included in this study. Electronic medical records were retrospectively reviewed and the mutational status *EGFR* and *KRAS* were defined. **Results:** We detected *EGFR* mutation in 20 samples (15.7%), and *KRAS* mutation in 26 samples (21.5%). The majority of *EGFR* mutations was detected within the exon 19 (n=9, 45.0%), and for *KRAS* G12V (n=8, 30.8%) and G12C (n=8, 30.8%) were the hotspots. The median overall survival was 11 months. We did not detect any statistical differences in survival rates between mutated and wild-type tumors neither for *EGFR* (p=0.898) nor for *KRAS* (p=0.458). Only two patients had access to TKI and were considered outliers with the best survival rates. **Conclusion:** We described important information about NSCLC biological behavior in a population treated in a reference public cancer center in South Brazil. Studies like this highlight the magnitude that TKI treatment could have in the overall survival of patients with NSCLC after being introduced into the SUS. Future studies that address the economic impact of this issue are also needed. Here we also make a comparison of our results with other regions of Brazil that have different genetic backgrounds to evaluate the impact of targeted therapies.

**Keywords:** Lung Neoplasms, Genes, erbB-1, Kirsten murine sarcoma virus, Public Health, Brazil.

1. Hospital Erasto Gaertner, Departamento de Oncologia Clínica - Curitiba - Paraná - Brazil.
2. Faculdade Evangélica do Paraná, Curso de Graduação em Medicina - Curitiba - Paraná - Brazil.
3. Laboratorio Mantis Diagnosticos Avançados, Departamento de Biologia Molecular - Curitiba - Paraná - Brazil.

**Financial support:** This research was conducted with the support of AstraZeneca.

**Conflicts of interest:** No Conflict of interest.

**Correspondence author:** Thais Abreu Almeida. Hospital Erasto Gaertner.

Rua: Dr. Ovande do Amaral, 201 - Jardim das Americas, Curitiba - PR. Zip code: 81520-060. Phone: +55 41 984089773.

E-mail: thaisaalmeida@gmail.com.

**Received on:** October 29, 2018 | **Accepted on:** February 20, 2019

**DOI:** 10.5935/2526-8732.20190004

## RESUMO

**Objetivo:** Avaliar os testes genéticos é fundamental para o tratamento adequado do câncer de pulmão de não pequenas células (CPNPC) com inibidores da tirosina quinase (TKI). Dado que o acesso a esta avaliação ainda é limitado para aqueles que dependem do Sistema de Saúde Pública do Brasil, parece importante proporcionar às agências reguladoras informação epidemiológica y de prognóstico para guiar as políticas e diretrizes de saúde futuras no Brasil. Este trabalho tem como objetivo caracterizar as mutações de EGFR y KRAS em CPNPC y associá-las com as características demográficas y tumorais clínico-patológicas dos pacientes. **Métodos:** de 2004 a 2017, se incluíram neste estudo 237 pacientes com CPNPC metastático tratados no Hospital de Câncer Erasto Gäertner. Os prontuários electrónicos foram revisados retrospectivamente y se definiram os estados mutacionais EGFR y KRAS. **Resultados:** Detectamos a mutação EGFR em 20 amostras (15.7%) e a mutação KRAS em 26 muestras (21.5%). A maioria das mutações de EGFR foram detectadas no exão 19 (n = 9, 45.0%), y para KRAS G12V (n = 8, 30.8%) y G12C (n = 8, 30.8%) foram os pontos críticos. A mediana de supervivência global foi de 11 meses. Não detectamos nenhuma diferencia estadística nas taxas de supervivência entre tumores mutados e do tipo selvagem nem para EGFR (p = 0,898) nem para KRAS (p = 0,458). Só dois pacientes tiveram acesso à TKI y se consideraram valores atípicos com as melhores taxas de supervivência. **Conclusão:** descrevemos informação importante sobre o comportamento biológico do CPNPC numa população tratada em um centro público de referência de câncer no sul do Brasil. Estudos como este destacam a importância que o tratamento com TKI poderia ter na supervivência general dos pacientes com CPNPC depois da sua introdução no SUS. Também se necessitam estudos futuros que abordem o impacto económico deste problema. Aqui também realizamos uma comparação dos nossos resultados com outras regiões do Brasil que têm diferentes antecedentes genéticos para avaliar o impacto das terapias dirigidas.

**Descritores:** Neoplasias Pulmonares, Genes, erbB-1, Vírus do sarcoma murino de Kirsten, Saúde pública, Brasil.

## INTRODUCTION

In Brazil, lung cancer is a public health problem given its high incidence, morbidity and mortality. The estimative of new cases from the Brazilian NCI is 18.740 for men and 12.530 for women in 2018<sup>1</sup>. Smoking cigarettes is, by far, the leading cause of this neoplasm, but efforts have been made to comprehend the genetic and inflammatory mechanisms involved in carcinogenesis and prognosis.

Clinicopathologic aspects, such as performance status (PS), comorbidities, histopathologic subtypes and oncogenic driver mutations, are crucial information to guide the initial treatment. Epidermal growth factor receptor gene (*EGFR*) and *KRAS* are the most known activating driver mutations, considered biomarkers predictive of response to tyrosine kinase inhibitors (TKIs), a class of drugs that confers better survival than chemotherapy and less toxicity<sup>2</sup>.

Unfortunately, in Brazilian public health, the access to these new technologies is limited by cost, once the reimbursement from the Health Ministry is about half the cost of TKIs treatment for each NSCLC patient<sup>3</sup>. In this article, we describe real data on clinical and prognostic characteristics and their correlation with driver mutations in population with advanced NSCLC representative of Southern Brazil. This information has the potential to change the approach to NSCLC management in public institutions in Brazil.

## METHODS

This study aims to analyze frequencies of EGFR and KRAS mutations in a NSCLC population treated at a public comprehensive cancer center in Brazil, and to correlate the tumor genotypes with demographic and clinical-pathologic features. We conducted a retrospective study of all treated patients referred to the Erasto Gäertner Cancer Hospital from

January 2004 to December 2017, diagnosed as metastatic or recurrent NSCLC, according to the American Joint Committee on Cancer (AJCC) staging manual, version 7. The Erasto Gäertner Hospital at Curitiba, Paraná State, Brazil, provides cancer care to public health system and is a reference for the Southern Brazilian population. Ethics approval for the study was obtained from the local research ethics board under the inscription number 2320. The primary endpoint was to characterize *EGFR* and *KRAS* mutations in metastatic or recurrent NSCLC, suitable for palliative chemotherapy treatment. Secondary endpoints were to correlate *EGFR* and *KRAS* mutational status with individual demographic and clinical-pathologic features, and with relevant clinical endpoints (best treatment response and overall survival). The key exclusion criteria were defined with non-treated patients and cases in which formalin-fixed, paraffin-embedded tissue (FFPET) were not available or the genetic material was not viable for analyses.

By a retrospective chart review, we collected the patient's baseline and tumor characteristics, such as age, sex, ethnicity, comorbidities, smoking status, metastasis sites and histological subtypes. Ethnicity was classified as white, black or other. Registered comorbidities were chronic obstructive pulmonary disease (COPD), systemic arterial hypertension (SAH), diabetes, hypothyroidism, and second primary tumor and, for statistical analysis, they were grouped in "absent" (no comorbidity), "one or two" and "three or four" comorbidities subgroups. For smoking status, patients were classified as never smoker, previous or current smoker. The pack-years were calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. Metastatic sites were grouped by prognostic criteria in "lung and/or pleural metastasis only" (excluding other concomitant sites), "visceral" (i.e. liver, adrenal, lymph nodes), "central nervous system (CNS)" (with or without involvement of other sites) and "bones only" (excluding other concomitant sites). The histological diagnosis was based on the 2014 World Health Organization (WHO) classification as adenocarcinoma, squamous cell carcinoma (SCC) and undifferentiated (NOS) carcinomas. The PS was estimated according to the Eastern Cooperative Oncology Group (ECOG) classification. Systemic treatment protocols, including the type of chemotherapy, were collected. Outcomes including overall survival (OS), from the time of diagnosis to death, and progression-free survival (PFS) were recorded. The duration of PFS was defined as the time from diagnosis until the date of objective disease progression or death in the absence of progression, regardless of whether the patient had received another anticancer therapy before progression.

2592 NSCLC patients were referred to our hospital from 2004-2017 and 1398 were at an advanced or recurrent disease. Only 587 were able to perform chemotherapy treatment, and 273 of those have suitable FFPET for DNA extraction and analysis. Tumor samples from primary tumor or metastatic site biopsy or pulmonary surgery resection were collected in FFPET from our Pathology Service archives and analyzed for mutational status at the laboratory Mantis Diagnósticos Avançados, in Curitiba, Paraná State, Brazil. Reasons for not inclusions were depleted and tiny amount of tumor tissue material, and scarce or low quality DNA extracted from tumor samples interfering with the analysis. Procedures for tumor tissue microdissection and DNA extraction were done according established protocols. In summary, local pathologists defined the area of the tumor sample to be selected by optical microscopy in histological sections (stained by hematoxylin-eosin), and a number of tissue sections of 5-10 micra corresponding to the blocks were used for DNA extractions with the QIAmp® DNA Mini Kit (Qiagen; California, USA). Quantitative assay for *KRAS* gene point mutation in codons 12, 13 (exon 2) and 61 (exon 3) was performed with *KRAS* Pyro® Kit (QIAGEN). The *EGFR* Pyro® Kit (QIAGEN) was used for quantitative assay for *EGFR* point mutations in codons 719 (exon 18), 768 (exon 20), 790 (exon 20), 856-861 (exon 21) and deletion of exon 19 (del19). The analysis and identification of existing mutations in these codons were performed using the Software PyroMark® (QIAGEN Germany).

The quantitative variables were described by average, standard deviation, median, and amplitude. The comparison of two groups defined for the *EGFR* or *KRAS* mutation, in respect to the quantitative variables, was made using t-Student test for independent samples or non-parametric Mann-Whitney test. Categorical variables were analyzed considering Fisher test or Chi-Square test. Survival was described by Kaplan-Meier method and Cox regression model was used to determine mortality predictors. We excluded from the survival analysis the two outlier cases treated with gefitinib. A p-value with less than 0.05 was considered statistically significant. Statistical analyses were performed using the computational program Stata/SE v.14.1. StataCorp LP, USA.

## RESULTS

Considering the 587 patients who were able to perform chemotherapy, 273 had viable FFPET for DNA extraction and analysis and those were included in this article. The clinical characteristics of adenocarcinoma and SCC cases at baseline are presented in Table 1.

**Table 1.** Demographic characterization in adenocarcinoma, SCC and total population (n=273)

Characteristics	Adeno* n= 162	SCC* n=92	Undiffer. NOS* n=19	Total n=273	%	**p-value
Median age, years				60		
Min-Max				30-84		
Ethnicity <sup>§</sup>						
White	153	84	18	255	93.4	-
Black	6	3	0	9	3.3	
Other	3	4	1	8	2.9	
Gender						
Male	74	58	12	144	52.7	0.018
Female	88	34	7	129	47.3	
Comorbidities						
Absent	65	33	8	106	38.8	0.955
One or two	87	52	10	149	54.8	
Three or four	10	7	1	18	6.6	
Smoking status						
Never smoked	46	4	3	53	19.4	<0.00001
Previous/smoker	102	86	13	201	73.6	
Unknown	14	2	3	19	7.0	
Pack years, median				40		
Min-Max				0,5 - 224		
Performance status						
0 or 1	104	52	10	166	60.8	0.162
2	38	31	4	73	26.7	
3 or 4	9	7	3	19	7,0	
Unknown	11	2	2	15	5.5	
Metastases sites						
Lung/Pleural (only)	46	41	8	95	34.8	0.004
Visceral	58	34	9	101	37.0	
CNS	41	6	2	49	17.9	
Bones (only)	23	10	1	34	12.5	

<sup>§</sup>For one patient with SCC ethnicity is unknown. \*Adeno: adenocarcinoma; SCC: undifferentiated carcinomas, NOS. \*\* Chi-square test, p<0.05

In our population, median age was 60. White ethnicity was 93.4%, and male gender was 52.7%. The majority has at least one comorbidity (54.8%), and the most frequent was chronic obstructive pulmonary disease (COPD). Adenocarcinoma was diagnosed in 162 (59.3%), SCC in 92 (33.7%) and undifferentiated carcinomas in 19 (7.0%) patients. Previous or current smoker status was recorded in 201 cases (73.6%). Smoking was more frequent in SCC (93.5%) than adenocarcinoma (63.0%) [p value = 0.0001]. PS was 0 or 1 in 166 (60.8%) cases. CNS metastasis at diagnosis was detected in 49 (17.9%) patients for symptomatic patients based on clinical symptoms or neurological findings, since CNS scanning was not routine in our service. There is an association between gender, smoking status and metastases sites with histological subtypes (p=0.018; p<0.00001; p=0.004, respectively). The most common chemotherapy treatment scheme at first line therapy was a platinum-doublet (95.2%);

docetaxel for second line regimen (63.9%); and 2 cases received Gefitinib as second line therapy (2.4%) (Table 2).

Of the 127 tumors tested for EGFR, 20 resulted positive for any EGFR mutation (15.7%). Among the 121 available samples for KRAS analysis (since six samples were depleted after EGFR analysis), KRAS mutation was detected in 26 (21.5%). In only one tumor sample, concomitance of EGFR (G719A) and KRAS (G12C) mutations could be detected. Compared with wild-type tumors (WT), EGFR mutated tumors did not differ in the median age at diagnosis (60 years for WT vs. 57 years, p=0.513) or in those mutated for KRAS (60 years WT vs. 59.5 years, p=0.343). We also did not find any statistical difference for gender, smoking status, pack-years, histological subtypes (adenocarcinoma or SCC) or metastatic sites between mutated and wild type subgroups for either EGFR or KRAS (Table 3).

**Table 2.** Chemotherapy treatment scheme at first and second line therapy

Characteristics	Total	
	n	%
First Line Chemotherapy		
Platinum-doublet*	256	95.2
Other	13	4.8
Second Line Chemotherapy		
Platinum-doublet	20	24.0
Docetaxel	53	63.9
Gefitinib	2	2.4
Others**	8	9.7

\*Platinum-doublet were cisplatin or carboplatin and paclitaxel or etoposide or gemcitabine \*\*Others were monotherapy scheme: gemcitabine, vinorelbine, etoposide

**Table 3.** EGFR and KRAS mutation frequency according to population characteristics

Characteristics	EGFR	p-value*	KRAS	p-value*
	mut/wt (%mut/wt)		mut/wt (%mut/wt)	
Gender				
Male	10/57 (14.9/85.1)	0.812	13/51 (20.3/79.7)	0.826
Female	10/50(16.7/83.3)		13/44 (22.8/77.2)	
Smoking status				
Never smoked	6/21 (23.0/78.0)	0.234	8/18 (30.8/69.2)	0.276
Previous/smoker	12/81 (13.0/87.0)		16/68(19.0/81.0)	
Histology				
Adenocarcinoma	12/63 (16.0/84.0)	0.986	16/55 (22.5/77.5)	0.517
scc	6/34(15.0/85.0)		6/31 (16.2/83.8)	
Others**	2/10(16.7/83.3)		4/9 (30.8/69.2)	
Metastasis sites				
Lung/Pleural (only)	6/33 (15.4/84.6)	0.229	7/32 (17.9/82.1)	0.473
Visceral	7/45 (13.5/86.5)		9/40(18.4/81.6)	
SNC	2/19(9.5/90.5)		5/14 (26.3/73.7)	
Bones (only)	5/10(33.3/66.7)		5/9 (35.7/64.3)	

\*Chi-square test,  $p < 0.05$ . EGFR or KRASmut: mutated; EGFR or KRASwt: wild-type. \*\*Others: undifferentiated carcinomas, NOS.

Among mutated tumors for *EGFR* or *KRAS*, the most common metastatic site was visceral (35.0%) in both groups. Others metastatic sites observed in *EGFR* and *KRAS* mutated tumors were lung or pleural (30.0% and 27.0%, respectively), bones (25.0% and 19.0%, respectively), and CNS (10.0% and 19.0%, respectively). Although there was an expressive prevalence of CNS metastasis in *KRAS* mutated tumors compared with *EGFR*, frequencies did not reach statistical significance for any of those sites in both *EGFR* and *KRAS* mutated groups ( $p=0.838$ ).

In our population, the most frequent position of *EGFR* mutations was in exon 19 ( $n=9$ , 45.0%).

Other *EGFR* mutations were found in exon 21 ( $n=7$ , 35.0%), exon 20 ( $n=3$ , 15.0%) and exon 18 ( $n=1$ , 5.0%). In details, the mutations detected in exon 19 were del E746-A750 ( $n=5$ ), del L747-P753 (insS) ( $n=1$ ), del L747- A750 (insP) ( $n=2$ ), and a complex deletion in-frame c.2237\_2251 del15 (p.E746\_T751>A) ( $n=1$ ). In exon 21, the mutation L858R ( $n=5$ ) and L861Q ( $n=2$ ). In exon 20, S768I ( $n=3$ ); and exon 18, G719A ( $n=1$ ). For *KRAS*, the mutations detected on available samples were G12V ( $n=8$ , 30.8%), G12C ( $n=8$ , 30.8%), G12S ( $n=6$ , 23.1%) and G12D ( $n=4$ , 15.4%). The distribution of *EGFR* kinase domain mutations according to clinical and pathological characteristics is described in Table 4.

**Table 4.** EGFR mutation location and clinical-pathological characterization

	EGFRmut		
	Exon 18/21	Exon 19	Exon 20
Gender			
Male	3	4	3
Female	5	5	0
Smoking status			
Never smoked	5	6	3
Previous/smoker	3	3	0
Histology			
Adenocarcinoma	5	7	0
scc	3	1	2
Metastasis sites			
Lung/Pleural (only)	2	3	1
Visceral	4	2	1
CNS	1	1	0
Bones (only)	1	3	1

\*A statistical test could not be applied because of low-frequency cases in exon 20.

The median overall survival of the entire cohort was 11 months, and no statistical difference in survival was detected between *EGFR* mutated versus WT (12.4 months vs. 10.6 months;  $p=0.898$ ), or *KRAS* mutated versus WT (12.1 months vs. 10.7 months;  $p=0.458$ ). Some clinical variables significantly interfered with survival: PS 0 or 1 had more favorable prognosis than PS 2 or more ( $p<0.001$ ); and lung or pleural metastatic sites had better outcomes than visceral, CNS and bones ( $p=0.004$ ). Neither comorbidities number nor histological subtypes (adenocarcinoma or SCC) influenced overall survival. However, patients that had more than one metastatic site had worst prognosis compared with only one- metastatic site tumors. Kaplan-Meier curves are represented in figure 1.

## DISCUSSION AND CONCLUSION

Oncogenic drivers identification has redefined how we treat advanced NSCLC. Chemotherapy is no longer a standard therapy if a patient has an actionable driver mutation. Patients with a genotype-directed therapy have a decreased risk of death compared with patients with any oncogenic driver who did not receive genotype-directed therapy (HR, 0.69 [95% CI, 0.53-0.9],  $p=0.006$ )<sup>4</sup>. In this study, we aimed to determine the frequency of the most common oncogenic drivers, EGFR and KRAS, and clinical prognosis correlations.

In Brazil, EGFR mutation frequency ranges from 20 to 30%<sup>5</sup> and KRAS mutation is approximately 14-16% in Brazil and Latin America<sup>6,7</sup>. A multi-institutional Lung Cancer Mutation Consortium (LCMC) from USA<sup>4</sup> enrolled 1007 patients with metastatic lung adenocarcinoma and found 21% EGFR mutation and 25% KRAS mutation. In our study, EGFR mutation frequency was 15.7% and KRAS was 21.5%.

A possible explanation for the low *EGFR* mutation frequency is the high smoking burden of our population, since *EGFR* mutation is more common in non-smokers or light smokers. The high smoking burden also justifies the greater *KRAS* mutation frequency in our population. We found no correlation with *EGFR* or *KRAS* mutation and smoking status ( $p=0.234$  and  $p=0.276$ ). The tumor blocks quality may also have influenced our results, since 53.5% of patients enrolled were ineligible, due to insufficient tissue. Considering that this is a retrospective study, when this project began, biopsies were performed only to establish a diagnosis.


In the large LCMC study<sup>4</sup>, 28% of patients enrolled were ineligible, due to insufficient tissue and only 48% had complete genotyping performed, which demonstrates the difficulty to obtain lung tissue for molecular analysis.

Ethnicity influences EGFR and KRAS mutation frequency and treatment response. In LCMC<sup>4</sup>, EGFR mutation were highly associated with Asian race ( $p<0.001$ ) and KRAS mutation with white race ( $p=0.006$ ). In our study, total white race frequency was 93.4%, mainly because European influence in South Brazil, so it was not possible to determine the ethnicity difference in EGFR or KRAS mutated patients.

According to LCMC<sup>8</sup>, EGFR mutation is highly associated with female sex ( $p<0.001$ ) and no gender association was observed in KRAS ( $p=0.746$ ). In our study, we did not found correlation in EGFR or KRAS with gender ( $p=0.812$  and  $p=0.826$ , respectively).

In LCMC<sup>8</sup>, EGFR mutations were less associated with bone metastasis presence, and adrenal metastasis absence.

**Figure 1.** Overall survival and survival according to EGFR, KRAS and clinical presentation



Kaplan-Meier survival curves and Cox regression models. A. Overall survival; B. *EGFR* mutated versus *EGFR* wild-type; C. *KRAS* mutated versus *KRAS* wild-type; D. Performance status 0 and 1 versus PS 2 or more; E. Lung/pleural metastasis sites versus other (visceral, CNS, bones); F. One metastasis site versus two or more metastases sites.

They also found that *KRAS* mutation was correlated with bone metastasis. Retrospective data show that patients with intrapulmonary metastasis have a higher frequency of *KRAS* mutation<sup>9</sup> than patients with extrapulmonary metastasis (35.0% vs. 26.5%, p=0.0125). In our study, we did not find this correlation, but we observed that *KRAS* mutation was more frequent in patients with visceral metastasis (34.6%). Possibly, if there is an association between *EGFR* or *KRAS* mutation and metastasis site, this association should be weak.

In this study, the survival was calculated between prognostic variables. Regardless mutational status, one metastasis site versus multiple metastasis sites is considered a known favorable prognostic factor, especially if it is resectable<sup>10</sup>. In agreement with previous studies<sup>11</sup>, we found a higher overall survival in patients with single metastasis site versus multiple metastasis sites (p=0.018), and a higher overall survival for lung or pleural metastasis versus other metastasis sites (p = 0.004).

Another prognostic variable is PS. Initial PS evaluation is crucial for treatment choice and it affects overall survival. In our study, we reviewed only treated patients, and 60.8% of them were PS 0 or 1. This subgroup showed greater survival compared with PS 2, 3 or 4 patients ( $p < 0.001$ ).

Our median survival was 11 months and is similar with others survival data in Brazilian studies<sup>5</sup>. For EGFR we did not find survival differences between mutated and non-mutated groups (median, 12.4 months and 10.6 months, respectively,  $p = 0.898$ ), and as well as for KRAS (median, 12.1 months and 10.7 months, respectively,  $p = 0.458$ ).

Only in mid-2010, with the encouragement of pharmaceutical companies, molecular testing for advanced NSCLC adenocarcinoma started at our Institution, but public access to TKIs was still limited by costs. Thus, in our study, only two patients with EGFR mutation were treated with Gefitinib, a first-generation EGFR TKI, in the second line treatment. These two cases were male patients, smokers, one with L858R mutation (exon 21) and one with E746-A750 mutation (exon 19). Both patients had the study longest survival rates (12.4 months and 37.1 months, respectively). This highlights the great benefit of TKI therapy in survival in NSCLC patients compared to standard chemotherapy<sup>12,13</sup>.

The best responses to TKI targeting EGFR are in individuals with exon 19 deletions<sup>14</sup>. Point mutations in exons 18 and 21 are also predictive of TKI response, but to a lesser extent and with relatively limited published experience with EGFR TKI response<sup>15</sup>. L861Q (exon 21) mutation has insufficient response data<sup>16</sup>. Some mutations in exon 20, such as T790M, are known to be associated with acquired secondary resistance, and rarely detected in primary resistant tumors (<5.0%). Interestingly, S768I EGFR mutation (also in exon 20) confers little or no response to first-generation TKIs, but a great probability to respond to second-generation TKIs or Afatinib<sup>17</sup>. Afatinib therapeutic choice has been extended to include patients with NSCLC in metastatic setting whose tumors harbor rare EGFR mutations, such as G719X, L861Q, and S768I.

In our study, 45.0% of mutations detected in EGFR happen in exon 19 by distinct small deletions, including complex in-frame deletion p.E746\_T751>A, first described here. Point mutations frequencies in exon 18 (G719A,  $n = 1$ ) and exon 21 (L858R,  $n = 5$  e L861Q,  $n = 2$ ) were 40.0%, and 15.0% in exon 20 (all S768I). These findings are in agreement with frequencies in literature<sup>18</sup>, except for S768I mutation that is rare in other series (0.55%)<sup>18</sup>, but happen in 15.0% (three cases) in our study. The differences in risk factors or our population genetic background may explain this. In one case, exon 18 EGFR point mutation G719A was detected concomitantly with KRAS mutation G12C in the same sample.

This rare finding may be explained by intratumoral heterogeneity (by mutational events arising separately in at least two distinct clones), or because of two co-mutational events into a unique malignant cellular clone leading to EGFR pathway cooperative activation in both upstream and downstream of the RAS-RAF-MEK-MAPK signaling-pathway. Unfortunately, we could not repeat the analysis in this case due insufficient tissue remaining. A recent study including 17.664 lung cancer patients detected 2 to 3 concomitant driver mutations in almost 1% of the cases. The most common co-mutations occurred again with EGFR in this large cohort were PIK3CA ( $n = 28$ ), KRAS ( $n = 24$ ), ALK ( $n = 10$ ), and BRAF ( $n = 5$ ) mutations<sup>19</sup>.

Recently in Brazil, government regulatory agency Agencia Nacional de Vigilância Sanitária (ANVISA) approved an oral third-generation irreversible EGFR TKI as front-line treatment for advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R mutation. In the FLAURA study, a phase III randomized trial for advanced NSCLC<sup>20</sup>, osimertinib was compared with first-generation TKIs (gefitinib or erlotinib) and it could improve PFS (18.9 versus 10.2 months; HR 0.46, 95% CI 0.37-0.57) and response duration (17.2 versus 8.5 months) with fewer toxicities.

Our study has limitations because it was retrospective and we excluded a large number of cases because of scarce or depleted tissue material and because of insufficient quality (fragmentation) of DNA extracted from FFPET. Based on current international guidelines all advanced adenocarcinoma NSCLC should be tested for actionable drug targets (EGFR, ALK, and ROS1)<sup>2</sup>. According to the College of American Pathologists<sup>2</sup>, SCC patients can be tested for sensitivity mutations in case of uncertain of an adenocarcinoma component, especially when clinical features favored presence of EGFR mutation (female, never smoker or young patients). In our study, many blocks were scarce, and some could not be histologically reanalyzed, so we opted for including in our mutational test all NSCLC cases (adenocarcinoma and SCC). This may explain the low EGFR frequency in our study.

The analytical method sensitivity may also explain differences in EGFR mutational rates in literature. We choose pyrosequencing because of its sensitivity to detect a minimum of 5% mutated alleles. Recently, with the application of next generation sequencing (NGS) and other allele-specific-based assays, i.e. digital droplet polymerase chain reaction (ddPCR), sensitivity of much less than 1% have been feasible, allowing the screening of rare somatic mutated alleles in body fluids (plasma, urine) by liquid biopsy<sup>21</sup>. Thus, in situation of limited specimen, other laboratory platforms would be preferred to prevent false-negative results.

Despite this fact, pyrosequencing is faster, requires less DNA, and is less complex in terms of assay design and technical setup than others techniques. It can determine not only known *EGFR* hotspots, including exon 19 deletions and codon 719 substitutions, but also new mutations, like complex in-frame deletion p.E746\_T751>A. Ultimately, genetic laboratories must consider analytical sensitivity in their reports, mutational coverage and method limitations when evaluating *EGFR* mutation assays for adoption into the laboratory workflow. The small volume of viable tumor material for analysis demonstrates the importance of an excellent collection of tissue at the time of biopsy, storage, and the impact in sensitivity that liquid biopsy will bring in the next few years for molecular analysis of tumors.

Because the access of the SUS population to *EGFR* TKI was limited by cost, only two patients were treated with first generation TKI (Gefitinib). The absence of differences in NSCLC survival between the mutated and non-mutated *EGFR* groups treated with chemotherapy alone during a pre-TKI era suggests that they have similar biological behaviors, and that *EGFR* alone was not prognostic. Currently, in our hospital, we perform molecular analyzes (*EGFR*, *ALK*, *PD-L1*) in all patients with advanced NSCLC adenocarcinoma, in association with pharmaceutical companies, access to therapy with Gefitinib after detection of the *EGFR* mutation is provided by the hospital after negotiating spending with the drug.

We intend to evaluate in the future the impact of introducing *EGFR* TKI on our population overall survival. Considering that *EGFR* mutation frequency in our population was 15.7% and that in Brazilian literature mutated cases survival can vary from 30 to 60 months in best series<sup>5</sup>, a pharmacoeconomical analysis focusing these new target therapies introduction in the context of public health is urgently needed. Recently, Brazilian Society of Clinical Oncology (SBOC) is assisting the Ministry of Health to select drugs according to scientific evidences available and cost-effectiveness analysis, in order to guarantee the equity in accessibility to Brazilian population treated in SUS<sup>22</sup>. Similar studies in Brazil will be important to characterize more widely NSCLC genetic profiling in other populations and *EGFR* TKI treatment impact magnitude on clinical outcomes.

## AUTHOR'S CONTRIBUTION

**Thais Abreu Almeida:** Collection and assembly of data, Conception and design, Data analysis and interpretation, Final approval of manuscript, Manuscript writing, Provision of study materials or patient.

**Jeanine Marie Nardin:** Collection and assembly of data, Data analysis and interpretation, Manuscript writing, Provision of study materials or patient.

**Amanda Jurgensen:** Collection and assembly of data, Provision of study materials or patient.

**Janaina Takahashi:** Collection and assembly of data, Provision of study materials or patient.

**Juliana Jung:** Provision of study materials or patient.

**Graziele Losso:** Collection and assembly of data, Data analysis and interpretation, Manuscript writing, Provision of study materials or patient.

**José C. Casali-da-Rocha:** Conception and design, Data analysis and interpretation, Final approval of manuscript, Manuscript writing.

## REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* 2015;65(2):87-108.
2. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol.* 2018;13(3):323-58.
3. Ferreira CG. Lung cancer in developing countries: access to molecular testing. *Am Soc Clin Oncol Educ Book.* 2013;33:327-31.
4. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA.* 2014;311(19):1998-2006.
5. Araujo LH, Baldotto C, Castro G Jr, Katz A, Ferreira CG, Mathias C, et al.; Grupo Brasileiro de Oncologia Torácica. Lung cancer in Brazil. *J Bras Pneumol.* 2018;44(1):55-64.
6. Arrieta O, Cardona AF, Martín C, Más-López L, Corrales-Rodríguez L, Bramuglia G, et al. Updated Frequency of *EGFR* and *KRAS* Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). *J Thorac Oncol.* 2015;10(5):838-43.
7. Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH, Ojopi EB. Epidermal growth factor receptor and *KRAS* mutations in Brazilian lung cancer patients. *Clinics (Sao Paulo).* 2012;67(5):419-24.
8. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al.; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol.* 2015;10(5):768-77.
9. Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, et al. *KRAS*-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with *KRAS* mutation and bone metastasis. *Sci Rep [Internet].* 2017 Dec; [cited 2018 Jul 16];7:39721.

- Available from: <http://www.nature.com/articles/srep39721>
10. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol*. 2016;17(12):1672-82.
  11. He YY, Zhang XC, Yang JJ, Niu FY, Zeng Z, Yan HH, et al. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2014;15(6):441-7.
  12. Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. *Cancer Manag Res*. 2017;9:243-8.
  13. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947-57.
  14. Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. *Sci Rep [Internet]*. 2016 Dec; [cited 2018 Jul 15];6:36458. Available from: <http://www.nature.com/articles/srep36458>
  15. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol*. 2005;23(11):2493-501.
  16. Kancha RK, Peschel C, Duyster J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. *J Thorac Oncol*. 2011;6(2):387-92.
  17. Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. *Ther Adv Respir Dis*. 2016;10(3):256-64.
  18. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS J*. 2010;277(2):301-8.
  19. Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, et al. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. *J Thorac Oncol*. 2017;12(6):963-73.
  20. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al.; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(2):113-25.
  21. Kim SS, Choi HJ, Kim JJ, Kim MS, Lee IS, Byun B, et al. Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA. *Sci Rep*. 2018;8(1):543.
  22. Debiasi M, Reinert T, Kaliks R, Amorim G, Caleffi M, Sampaio C, et al. Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System. *J Glob Oncol*. 2016;3(3):201-7.